Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer
- PMID: 12944918
- DOI: 10.1038/sj.onc.1206858
Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer
Abstract
To examine the role of H-ras in the development of human ovarian cancer, we used small inhibitory RNA (siRNA) to silence its expression in human ovarian cancer cell lines and assessed the effects of its silencing on proliferation, apoptosis, and tumorgrowth. First, we developed a retrovirus-based delivery system that allowed long-term stable expression of the desired siRNA. Retrovirus-mediated expression of siRNA against green fluorescence protein (GFP) reduced its expression more than 90% in four cancer cell lines. We then constructed three retroviruses that expressed siRNAs targeting the H-rasV(12) mutation (H1/siRNA) or either of two wild-type sequences of the H-ras gene (H2/siRNA and H3/siRNA) and used these retroviruses to infect T80H and SKOV-3 cells. In T80H cells (a genetically transformed human ovarian surface epithelial cell line whose tumorigenicity depends on H-rasV(12) expression), infection with the H1/siRNA and H2/siRNA, but not with H3/siRNA, decreased T80H proliferation, increased G(0)/G(1) arrest and apoptosis, blocked transformation in vitro, and suppressed tumor growth in nude mice. In SKOV-3 cells (a human ovarian cancer cell line that contains high levels of wild-type H-ras protein but no H-rasV(12) mutation), introduction of the H2/siRNA construct, but not H1/siRNA or H3/siRNA, produced similar effects, demonstrating that the suppression of tumorgrowth by siRNA was sequence-specific. We conclude that H-ras is involved in maintenance of tumorgrowth of human ovarian cancer, and that retrovirus-mediated siRNA expression against H-ras expression is a powerful tool to dissect ras-signaling pathways and may be used therapeutically against ovarian cancer.
Similar articles
-
Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.Cancer Res. 2006 Oct 1;66(19):9736-43. doi: 10.1158/0008-5472.CAN-06-1617. Cancer Res. 2006. PMID: 17018633
-
Silencing of N-Ras gene expression using shRNA decreases transformation efficiency and tumor growth in transformed cells induced by anti-BPDE.Toxicol Sci. 2008 Oct;105(2):286-94. doi: 10.1093/toxsci/kfn122. Epub 2008 Jun 20. Toxicol Sci. 2008. PMID: 18567617
-
Stable suppression of HER-2 gene expression using siRNA increases the lysis of human ovarian carcinoma cells mediated by NK-92 cell line.Oncol Rep. 2008 Dec;20(6):1425-31. Oncol Rep. 2008. PMID: 19020724
-
The association of the H-ras oncogene and steroid hormone receptors in gynecological cancer.J Exp Ther Oncol. 1996 Nov;1(6):335-41. J Exp Ther Oncol. 1996. PMID: 9414422 Review.
-
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer.Cancer Treat Rev. 2010 Feb;36(1):8-15. doi: 10.1016/j.ctrv.2009.10.005. Epub 2009 Nov 28. Cancer Treat Rev. 2010. PMID: 19945796 Review.
Cited by
-
The therapeutic potential of RNA interference.FEBS Lett. 2005 Oct 31;579(26):5996-6007. doi: 10.1016/j.febslet.2005.08.004. Epub 2005 Aug 15. FEBS Lett. 2005. PMID: 16115631 Free PMC article. Review.
-
ETS transcription factors: possible targets for cancer therapy.Cancer Sci. 2004 Aug;95(8):626-33. doi: 10.1111/j.1349-7006.2004.tb03320.x. Cancer Sci. 2004. PMID: 15298723 Free PMC article. Review.
-
RNA interference: from gene silencing to gene-specific therapeutics.Pharmacol Ther. 2005 Aug;107(2):222-39. doi: 10.1016/j.pharmthera.2005.03.004. Pharmacol Ther. 2005. PMID: 15908010 Free PMC article. Review.
-
Targeting the RAS oncogene.Expert Opin Ther Targets. 2013 May;17(5):507-31. doi: 10.1517/14728222.2013.764990. Epub 2013 Jan 30. Expert Opin Ther Targets. 2013. PMID: 23360111 Free PMC article. Review.
-
HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo.Oncotarget. 2016 Jul 19;7(29):45186-45198. doi: 10.18632/oncotarget.9870. Oncotarget. 2016. PMID: 27286256 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous